# Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

> **NCT05809895** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Ociperlimab
- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Placebo
- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05809895
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-15
- **Primary completion:** 2029-07-17
- **Final completion:** 2029-07-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809895, "Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05809895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*